CPIC abacavir & HLA-B guideline update published
CPIC has extensively reviewed the literature and concluded no changes are required to the therapeutic recommendations of the abacavir dosing guideline based on HLA-B genotype since the original publication in 2012.
The 2014 update includes the following additions:
* Clinical implementation resources to help implementation of the guidelines into an